This is a study of Hemophilia Treatment Center patients, demographics and health services from 1990 to 2010 courtesy of the journal Haemophilia.
Summary. For several decades, US government agencies have partially supported regional networks of Hemophilia Treatment Centers (HTC). HTC multidisciplinary teams provide comprehensive and coordinated diagnosis, treatment, prevention, education, outreach and surveillance services to improve the health of people with genetic bleeding disorders. However, national data are scarce on HTC-patient population trends and services. The aim of the study was to examine national trends over the past 20 years in patient diagnoses, demographics and health services utilization among the Health Resources and Services Administration (HRSA) and Centers for Disease Control and Prevention (CDC)-supported HTC network. Diagnoses, demographics and health services utilization data from 1990 to 2010 were aggregated from all HTCs using the Hemophilia Data Set (HDS). From 1990 to 2010, the HTC population grew 90%from 17 177 to 32 612. HTC patients with von Willebrand’s disease increased by 148%, females by 346%, Hispanic patients by 236%and African Americans by 104%. Four thousand and seventyfive deaths were reported. From 2002 to 2010, annual comprehensive evaluations grew 38%, and persons with severe haemophilia on a home intravenous therapy programme rose 37%. In 2010, 46%of patients were less than 18 years vs. 24%for the general US population. The Hemophilia Data Set documents the growth and diversity of the US Hemophilia Treatment Center Network’s patient population and services. Despite disproportionate deaths due toHIV, theHTC patient base grew faster than the general US population. The HDS is a vital national public health registry for this rare-disorder population.
Full Study: HDS Trends